Heart Bypass Surgery Clinical Trials

Clinical trials related to Heart Bypass Surgery Procedure

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years old

• CABG with IMA-LAD graft in MIDCAB technique

• Age ≥18 years old

• CABG with IMA-LAD graft in MIDCAB technique

• Signed informed consent

Locations
Other Locations
Switzerland
Istituto Cardiocentro Ticino
RECRUITING
Lugano
Contact Information
Primary
Marco Valgimigli, Prof Dr Med
marco.valgimigli@eoc.ch
+41 91 811 51 11
Backup
Servizio di Ricerca Cardiovascolare Cardiocentro
enrico.frigoli@eoc.ch
+41 (0)91 811 53 04
Time Frame
Start Date: 2024-05-12
Estimated Completion Date: 2028-01-01
Participants
Target number of participants: 30
Treatments
Cangrelor MIDCAB Group (Prospective Cases)
Patients prospectively enrolled to undergo MIDCAB surgery while receiving continuous cangrelor infusion at 0.75 μg/kg per minute. All prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily with Multiplate® testing. Data collected include perioperative safety, bleeding outcomes, laboratory values, and clinical events.
Aspirin MIDCAB Group (Historical Controls)
Retrospective patients who previously underwent MIDCAB surgery under aspirin therapy, with or without prior bridging with cangrelor. Relevant perioperative and clinical data are extracted from the institutional database for comparison with the prospective cases.
Sponsors
Leads: Cardiocentro Ticino

This content was sourced from clinicaltrials.gov